• Rescheduled API purchases from April 2026 and January 2027 to December 2027 and December 2028
• No API purchases required before December 2027
• Continuing activities to establish an additional API supplier for Sofpironium Bromide

Botanix Pharmaceuticals Limited (ASX:BOT) has announced the successful renegotiation of its API supply agreement with its current supplier, Kaken Pharmaceutical Co., Ltd. The key highlights of the amended agreement include:- Two API purchases previously scheduled for April 2026 and January 2027 have been rescheduled for December 2027 and December 2028, with no API purchases required before December 2027.- Botanix is continuing its activities to establish an additional API supplier for Sofpironium Bromide, with the aim of de-risking the supply chain, potentially reducing the cost of goods sold by 25-40%, and increasing gross profit.- As part of the amendment, Botanix will consult with the current API provider on the selection of the additional supplier and receive technical support.- Deferring the upcoming API purchases, along with the proceeds from the current capital raise (if approved), is expected to strengthen Botanix's ability to pursue its outlined plans for Sofdra and the fulfilment platform.Botanix is grateful for the ongoing strong relationship with Kaken Pharmaceutical and is focused on effective management of working capital to support the launch and expansion of its dermatology products.

Botanix is continuing its activities to establish an additional API supplier for Sofpironium Bromide, with the aim of de-risking the supply chain, potentially reducing the cost of goods sold by 25-40%, and increasing gross profit.